<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055741</url>
  </required_header>
  <id_info>
    <org_study_id>1401CS-2</org_study_id>
    <nct_id>NCT03055741</nct_id>
  </id_info>
  <brief_title>Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIb, Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daehwa Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daehwa Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of DHP1401 in patients
      with mild-moderate Alzheimer's disease treated with donepezil
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-cognition Korean version(ADAS-cog)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating Sum of Box Korean version(CDR-SB)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory-Q Korean version(NPI-Q)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K-MMSE</measure>
    <time_frame>6 months</time_frame>
    <description>Korean Mini-Mental State Examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Korean Instrumental Activity of Daily Living(K-IADL)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Korean Trial Masking Test-elderly's version(K-TMT-e)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Mild-moderate Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks
DHP1401: Total 500mg is orally administrated in two divided doses a day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks
DHP1401: Total 1,000mg is orally administrated in two divided doses a day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks
DHP1401: Placebo is orally administrated in two divided doses a day for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>5mg or 10mg, once a day, 24 weeks</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Aricept®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHP1401</intervention_name>
    <description>Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>DHP1401 500mg or 1,000mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo was administrated in two divided dosed a day for 24 weeks</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>DHP1401 placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥55 and ≤85 years of age

          2. Patient who was diagnosed mild to moderate Alzheimer's disease by National Institute
             of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related
             Disorders Association(NINCDS-ADRDA) or National Institute on Aging-Alzheimer's
             Association(NIAAA)

          3. Korean Mini-Mental State Examination(K-MMSE) score 15 to 26

          4. Patient who maintained on donepezil without dose escalation or reduction for at least
             during 3 months before screening (visit 1)

          5. Clinical Dementia Rating(CDR) score 0.5 to 2.0 at screening (visit 1)

          6. Written informed consent voluntarily

          7. Patient who has a relative/caregiver who support the information of patient's status

          8. Patient who are deemed adequate to participate in the clinical trial by the
             investigator

          9. Infertility or patients and his/her spouse consent with contraception during the study
             period

        Exclusion Criteria:

          1. A diagnosis of vascular dementia or dementia by other cause according to the criteria
             of the NINCDS-ADRDA

          2. Structural brain abnormality or impairment

          3. Schizophrenia, depressive disorder and bipolar disorder

          4. Any neurological disease except Alzheimer' disease (ex. Parkinson's disease,
             Huntington's disease, brain tumor, normal-pressure hydrocephalus, progressive
             supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, epilepsy,
             delusion and head injury required hospitalization)

          5. History of any cancer within previous 5 years

          6. History of stroke within previous 2 years

          7. Heart failure required medication or interventional treatment including myocardial
             infarction, valvular heart disease, arrhythmia within previous 1 year

          8. Uncontrollable diabetes

          9. Uncontrollable hypertension

         10. Abnormal liver or kidney function

         11. Patient with significant clinical meaning to affect cognitive function

         12. Patient who participated in other clinical trial within previous 3 months or has a
             plan to participate in other clinical trial during study period

         13. History of abuse of a drug or alcohol within previous 2 years

         14. Patient who has administrated other acetylcholinesterase inhibitors except donepezil
             within previous 4 weeks

         15. Patient who are deemed inadequate to participate in the clinical trial by the
             investigator(ex. a illiteracy, etc.)

         16. History of hypersensitivity reaction to the main ingredient of the investigational
             drugs

         17. Patient who has administrated other drugs except donepezil for dementia treatment (it
             is possible to enroll after washout for 28 days)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seol Heui Han, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seol Heui Han, M.D., Ph.D</last_name>
    <phone>82-2-2030-7007</phone>
    <email>20050102@kuh.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Catholic University of Korea, Bucheon, ST. Mary's Hospital</name>
      <address>
        <city>Bucheon-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-Soo Shim, M.D., Ph.D.</last_name>
      <phone>82-32-340-7094</phone>
      <email>ysshim@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Myongji Hospital</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Jeong Han, M.D., Ph.D.</last_name>
      <phone>82-31-810-5403</phone>
      <email>neurohan@mjh.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SangYun Kim, M.D., Ph.D.</last_name>
      <phone>82-31-787-7462</phone>
      <email>neuroksy@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Medical Center</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Sung Lim, M.D., Ph.D.</last_name>
      <phone>82-31-219-4493</phone>
      <email>lts0204@aumc.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju-si</city>
        <state>Jeollanam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byeong Chae Kim, M.D., Ph.D.</last_name>
      <phone>82-62-220-6123</phone>
      <email>byeckim@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung Won Park, M.D., Ph.D.</last_name>
      <phone>82-51-240-2966</phone>
      <email>neuropark@dau.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kee Hyung Park, M.D., Ph. D.</last_name>
      <phone>82-32-460-8683</phone>
      <email>khpark@gachon.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong-Hye Choi, M.D., Ph.D.</last_name>
      <phone>82-32-890-3659</phone>
      <email>seonghye@inha.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee-Jin Kim, M.D., Ph.D.</last_name>
      <phone>82-2-2290-8374</phone>
      <email>hyumcbrain@hanyang.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kun-Woo Park, M.D., Ph.D.</last_name>
      <phone>82-2-926-5347</phone>
      <email>kunu@korea.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Won Yang, M.D., Ph.D.</last_name>
      <phone>82-2-2258-6077</phone>
      <email>neuroman@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

